PDS Biotechnology published Phase 2 VERSATILE-002 results for PDS0101 plus pembrolizumab, reporting 39.3 months median overall survival in the overall CPS ≥1 population. The publication matters to investors because PDS Biotech says it is pursuing partnerships for PDS0101 while prioritizing PDS0301 in metastatic colorectal cancer.

Key Highlights

  • Objective response reached 36% for the CPS ≥1 population, with complete responses recorded under investigator review.
  • VERSATILE-002 reported median overall survival of 39.3 months in the overall CPS ≥1 population.
  • Objective response rate was 36% under investigator review and 34% under central review.
  • Grade 3 or higher treatment-related adverse events occurred in 13.8% of patients, with no Grade 5 treatment-related adverse events reported.

PDS Biotechnology Corp. (NASDAQ: PDSB) is a Pharmaceuticals: Major company. Results from its VERSATILE-002 Phase 2 trial of PDS0101 with pembrolizumab showed median overall survival of 39.3 months in the overall CPS ≥1 population. PDS Biotech said it will prioritize PDS0301 in metastatic colorectal cancer while pursuing a Partnership strategy for PDS0101.

Response and

Safety Measures The objective response rate for CPS ≥1 was 36% under investigator review and 34% under central review. The cited standard-of-care pembrolizumab result for the same population was 19%, while the cited median overall survival result for standard pembrolizumab or pembrolizumab plus chemotherapy was 17.9 months. Grade 3 or higher treatment-related adverse events occurred at a 13.8% rate, compared with 17% in the cited standard-of-care safety result, and no Grade 5 treatment-related adverse events were reported. The company said no head-to-head trials had been performed.